Disease Domain | Count |
---|---|
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Chemical drugs | 1 |
Top 5 Target | Count |
---|---|
MKK4(mitogen-activated protein kinase kinase 4) | 2 |
Target |
Mechanism MKK4 inhibitors |
Active Org. HepaRegeniX GmbHStartup |
Originator Org. HepaRegeniX GmbHStartup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MKK4 inhibitors |
Active Org. |
Originator Org. HepaRegeniX GmbHStartup [+1] |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MKK4 inhibitors |
Active Org.- |
Originator Org. HepaRegeniX GmbHStartup |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Nov 2024 |
Sponsor / Collaborator HepaRegeniX GmbHStartup |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
HRX-215 ( MKK4 ) | liver function failure More | Phase 1 |
HRX-0233 ( MKK4 ) | Neoplasms More | Preclinical |
Darizmetinib ( MKK4 ) | Nonalcoholic Steatohepatitis More | Pending |